Patient Engagement

Changing customer preferences and a growing need for specialized knowledge are challenging the traditional scope of the medical affairs function. Learn about six ways pharma MA departments can drive more collaborative relationships with caregivers.

Perspectives from big pharma and the rare disease space on how patient advocacy is evolving as a corporate function.

Working group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.

Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.

That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.

Benchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.

How patient support programs have changed over the past two decades, considering adding safety data collection to the mix, and what regulations are driving pharma to adopt pharmacovigilance.

Hilary Hutton-Squire, Gilead’s UK & Ireland General Manager, talks to Pharm Exec about the company's new "HIV Age Positively" campaign.

The need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.

Designing and managing clinical outcome assessments on an international basis is more than a translation task. It requires the more discrete practice of linguistic validation, writes Dana Weiss.

DIA’s global chief executive talks with Pharm Exec about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its benefits in everyday practice.

Outlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”

China's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.

From AI to Alexa, experts in specialty pharma ponder the possibilities for high tech and the patient journey.

Addressing adherence with c-suite sponsorship and at scale has the capacity increase revenue, improve patient outcomes and lower health care costs, writes Tom Kottler.

The pharmaceutical industry needs to be paying more attention to consumer purchase habits.

Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas. 

With digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.

How “patient influencers” look beyond price to help the industry evaluate newly-launched brands.

A description of the changing role of the medical affairs function in pharmaceutical companies and the subsequent evolution to a never ending measurement of the output of medical affairs. How to overcome this quest for sometimes meaningless numbers to justify its existence.

There is a real opportunity for pharma to support the under-served population of atopic dermatitis patients, writes Mariel Metcalfe.

And ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders-most importantly, patients and the wider public.

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

Program puts a new-and very real-spin on patient nutrition.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.